Standard Biotools (LAB) Income from Continuing Operations (2010 - 2026)

Standard Biotools (LAB) has reported Income from Continuing Operations for 17 consecutive years, with -$21.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 21.85% year-over-year to -$21.5 million in Q2 2026; TTM through Jun 2026 was -$53.9 million, a 23.57% increase from a year earlier, with the FY2025 full-year figure at -$58.8 million, up 17.63% from the prior year.
• Income from Continuing Operations was -$21.5 million for Q2 2026 at Standard Biotools, down from -$14.6 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at $13.9 million in Q4 2025 and troughed at -$76.3 million in Q1 2022.
• A 5-year average of -$23.9 million and a median of -$21.3 million in 2023 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations plunged 305.82% in 2022 and soared 282.48% in 2025, its largest moves.
• Over 5 years, Income from Continuing Operations stood at -$20.8 million in 2022, then jumped by 82.05% to -$3.7 million in 2023, then tumbled by 103.64% to -$7.6 million in 2024, then soared by 282.48% to $13.9 million in 2025, then sank by 254.92% to -$21.5 million in 2026.
• The last three Income from Continuing Operations figures came in at -$21.5 million (Q2 2026), -$14.6 million (Q1 2026), and $13.9 million (Q4 2025), per Business Quant data.